- Report
- February 2024
- 175 Pages
Global
From €4766EUR$5,000USD£4,088GBP
- Report
- January 2024
- 175 Pages
Global
From €4766EUR$5,000USD£4,088GBP
- Report
- May 2024
- 185 Pages
From €3216EUR$3,374USD£2,759GBP
€3573EUR$3,749USD£3,065GBP
- Report
- July 2022
- 163 Pages
Global
From €3036EUR$3,185USD£2,604GBP
€4337EUR$4,550USD£3,720GBP
- Report
- October 2022
- 110 Pages
Asia Pacific
From €2002EUR$2,100USD£1,717GBP
€2859EUR$3,000USD£2,453GBP
- Report
- October 2020
- 420 Pages
Global
From €3812EUR$4,000USD£3,270GBP
- Report
- January 2024
- 93 Pages
Global
From €3500EUR$3,934USD£3,107GBP
Epirubicin is an oncology drug used to treat a variety of cancers, including breast, ovarian, and bladder cancer. It is a type of anthracycline, a class of chemotherapy drugs that work by interfering with the growth of cancer cells. Epirubicin is administered intravenously and is often used in combination with other chemotherapy drugs. It is also used in the treatment of metastatic cancer, which is cancer that has spread to other parts of the body.
Epirubicin is generally well tolerated, but can cause side effects such as nausea, vomiting, hair loss, and fatigue. It can also cause damage to the heart, so it is important to monitor patients closely for any signs of cardiac toxicity.
The epirubicin market is highly competitive, with many companies offering generic versions of the drug. Some of the major players in the market include Pfizer, Novartis, Teva Pharmaceuticals, and Mylan. Show Less Read more